High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.
about
Emerging drugs for uveitisCellular targeting in autoimmunityTreatment of Juvenile Idiopathic Arthritis-Associated UveitisAn anti-interleukin-2 receptor drug attenuates T- helper 1 lymphocytes-mediated inflammation in an acute model of endotoxin-induced uveitisAn update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.Pharmacotherapy for uveitis: current management and emerging therapy.Autoimmune and autoinflammatory mechanisms in uveitis.Diagnostic techniques for inflammatory eye disease: past, present and future: a review.Juvenile idiopathic arthritis-associated uveitis.Key role for IL-21 in experimental autoimmune uveitis.Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory diseaseClinical trials in noninfectious uveitisWhat do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Cutaneous adverse events in multiple sclerosis patients treated with daclizumabCurrent perspectives on ophthalmic manifestations of childhood rheumatic diseasesPrevention and management of cataracts in children with juvenile idiopathic arthritis-associated uveitisUpdate on the use of systemic biologic agents in the treatment of noninfectious uveitis.Cutting-edge issues in autoimmune uveitis.Importance of recognizing and preventing blindness from juvenile idiopathic arthritis-associated uveitis.The role of biologic agents in the management of non-infectious uveitis.Systemic treatment of vitreous inflammation.New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment.A systematic review of biologics for the treatment of noninfectious uveitis.Pediatric uveitis: new and future treatments.Systemic treatments for noninfectious vitreous inflammation.A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis.Investigational drugs for treatment of juvenile idiopathic arthritis.Use of biologic agents in ocular manifestations of rheumatic disease.[Evidence of treatment of chronic inflammation in childhood and adolescence with biologics].Challenges of childhood uveitis.Treatment strategies for childhood noninfectious chronic uveitis: an update
P2860
Q24630848-8E4B8847-EE9F-4B26-B0E6-CAD0228434E1Q26824580-9F40EF86-7448-4CD9-82F4-F40CB597081DQ28080084-3D2C17BC-C4DB-44A4-BDA3-41723FDA2F7EQ28540312-3EC82775-F4D3-4122-99F9-E7721D25D6C4Q33910781-66FF7B18-15C8-4FCF-A27F-F634A4A07B3AQ34274075-52FDFC97-AD33-47CE-A07E-62A7B103FC51Q34294964-D986344C-A04C-476E-8067-AB946CC3645BQ34910419-CB201D4B-81CC-406F-B065-F1AAAB585FF7Q34950552-91F883D4-4826-49D8-84FB-AD8E102D54C9Q35035122-BB9B689E-E06A-474C-87B6-0E2A3C541465Q35215459-847A3778-477A-466E-8585-56F6E7050978Q35681664-DF3B316F-DE44-44AB-A174-82E60A1C02BFQ36396476-B07D1013-37ED-4213-95A4-1BD07C9CBC58Q36691970-87F41AAA-D41F-44B7-8AB4-2B156F8D007FQ37007652-DD5E1420-DD15-4378-B646-03A07C85E163Q37115017-E23318AA-56B5-48C7-8803-08F857F30064Q37600483-0B8F700A-E637-4183-A532-2B48B36CAE43Q37931096-23ABBE33-0C01-4A61-9F9F-EC1E556C3624Q37974586-9EF9F0AD-152B-4798-928A-492DF674B3E6Q38025152-8B3F7C00-FC6E-4004-BDF9-7E31D9054AFFQ38048774-172F8B6B-F612-49AB-B714-6F14FF3D8C78Q38057370-31277DB7-0429-4D7D-855D-029EB68D6A0BQ38068969-63DC1984-1374-4176-9B41-7FAF8FB72CF0Q38123032-42B0CE21-63F7-4F63-BAE2-E52C0076F582Q38172090-3B663F16-C2DB-475A-9FDA-3DBE7C4669EDQ38250103-6DB89188-45BF-4A3A-97FB-973C4CB4F2B4Q38773144-4F53E923-3929-40AC-9561-007F4893022CQ38917814-B7BA9F6E-F9B7-40F1-B144-14A71EA904EAQ40008319-E4BCB570-6D9C-466F-82CB-8641DED4773FQ40179129-3A061836-6104-4D92-84FA-DEBADC71B440Q42714905-7972BFF0-6ECF-4879-8E0D-1DB873811B0FQ58326249-5A2DCE2B-296E-498C-9812-26015DDC716C
P2860
High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
High-dose daclizumab for the t ...... iated active anterior uveitis.
@ast
High-dose daclizumab for the t ...... iated active anterior uveitis.
@en
High-dose daclizumab for the t ...... iated active anterior uveitis.
@nl
type
label
High-dose daclizumab for the t ...... iated active anterior uveitis.
@ast
High-dose daclizumab for the t ...... iated active anterior uveitis.
@en
High-dose daclizumab for the t ...... iated active anterior uveitis.
@nl
prefLabel
High-dose daclizumab for the t ...... iated active anterior uveitis.
@ast
High-dose daclizumab for the t ...... iated active anterior uveitis.
@en
High-dose daclizumab for the t ...... iated active anterior uveitis.
@nl
P2093
P2860
P50
P1476
High-dose daclizumab for the t ...... iated active anterior uveitis.
@en
P2093
John G Ryan
Karyl S Barron
Keri Hammel
Lisa J Faia
Steven Yeh
Zhuqing Li
P2860
P304
696-703.e1
P356
10.1016/J.AJO.2009.06.003
P407
P577
2009-08-06T00:00:00Z